期刊文献+

TP、PTP及CAP化疗方案治疗上皮性卵巢癌的比较 被引量:2

Comparison of comMnation therapy with TP, PIP and CAP in patients with epithelial ovarian cardnoma
下载PDF
导出
摘要 目的探讨进口紫杉醇(泰素)与铂类联合化疗方案(TP)、国产紫杉醇(紫素)与铂类联合化疗方案(PIP)治疗上皮性卵巢癌的疗效及毒性,并与环磷酰氨、阿霉素及铂类方案(CAP)进行比较。方法对1993年12月至1999年4月采用TP、PIP及CAP化疗方案治疗的卵巢癌患者进行回顾性分析。泰素组(TP组)22例、紫素组(PTP组)18例,CAP组38例。结果泰素组有效率为55.6%,紫素组有效率为71.4%;紫杉醇作为一线用药有效率为88.9%,CAP作为一线用药有效率为55.9%。紫杉醇的毒副作用有造血功能抑制、消化道症状、脱发、外周神经炎、肌肉、关节疼痛,其中2例出现Ⅲ度外周神经损伤。结论TP或PTP作为一线用药疗效高于CAP,国产及进口紫杉醇在疗效及副作用上无明显差异。 Objective To study the effect and toxicities of paclitaxel (USA) combined with platinum (TP) and paclitaxel (Chinese) combined with platinum (PTP) in the treatment of epithelial ovarian cancer, and to compare with the combination of cyclophosphamidex adriamycin and platinum ( CAP ) .Methods A retrospective analysis in the treatment of ovarian cancer with paclitaxel and CAP from December 1993 to April 1999 was done. Including 22 patients in TP group, 18 patients in PIP group and 38 patients in CAP group.Results The response rate ( RR ) in TP group was 55.6%, while the RR in FTP group was 71.4%. In first line chemotherapy, the RR in paclitaxel groups was 88.9% , but 55.9% in CAP group . Besides myelosuppres-sion, nausea, vomiting and alopecia, the main side - effects of paclitaxel were : peripheral neuritis, myalgia and arthralgia, grade 3 peripheral neuropathy were found in two patients.Conclusions Paclitaxel in combination with platinum is clinically more effective than the standard therapy with CAP in first line chemotherapy for the treatment of ovarian cancer . The results showed no apparent differences in the effect and toxicity for two kinds of paclitaxel .
出处 《中国妇产科临床杂志》 2001年第5期283-285,291,共4页 Chinese Journal of Clinical Obstetrics and Gynecology
关键词 上皮性卵巢癌 紫杉醇 毒性作用 Epithelial Ovarian Cancer Paclitaxel Toxicities
  • 相关文献

参考文献12

  • 1[4]孙燕,周际昌.临床肿瘤内科手册.北京:人民卫生出版社,1997.53~54. 被引量:5
  • 2[2]Schiff PB, Fant J, Horwitz SB, et al. Promotion of microtubule assembly in unitro by taxol. Nature, 1979, 277:655-667 被引量:1
  • 3[3]Wiernik PH, Schwartz EL, Strauman JJ, et al. Phase I clinical and pharmcokinetic study of taxol. Cancer Res, 1987, 47: 2486- 2493 被引量:1
  • 4[4]Zamagni C, Martoni A, Cacciari N, et al. The combination of paclitaxel and carboplatin as first - line chemotherapy in patients with stage Ⅲ and stage Ⅳ ovarian cancer: A phase Ⅰ - Ⅱ study. Am J Clin Oncol,1998, 21: 491 - 497 被引量:1
  • 5[5]Fennelly DW, Aghajanian C. Dose escalation of paclitaxel with high dose carboplatin using peripheral blood progenitor cell support in patients with advanced ovarian cancer. Semin Oncol, 1997, 24 (suppl 2): 26-30 被引量:1
  • 6[6]Rowinsky EK, Donehower RC. The clinical pharmcology of paclitaxel. Semin Oncol, 1993, 20(suppl 3): 16 被引量:1
  • 7[7]Markman M, Kennedy A.Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience. Semin Oncol,1997, 24 (suppl 15): 26-29 被引量:1
  • 8[8]Trope C, Kaem J. Paclitaxel in untreated FIGO stage Ⅲ suboptimally resected ovarian cancer. Ann Oncol, 1997, 8: 803 - 806 被引量:1
  • 9[9]Ezcurdia L, Jovtis SL. Paclitaxel in platinum- resistant ovarian cancer patients. Argentine Multicenter Taxol Group. Semin Oncol, 1997, 24(Suppl 15): 53- 56 被引量:1
  • 10[10]Mayerhofer K, Kucera E. Taxol as second- line treatment in patients with advanced ovarian cancer after platinum- based first - line chemotherapy. Gynecol Oncol, 1997, 64: 109- 113 被引量:1

共引文献4

同被引文献18

  • 1Clark TG, Stewart ME, Altman DG, et al. A prognostic model for ovarian cancer. Br J Cancer, 2001,85:944-952. 被引量:1
  • 2De Laurentiis M, De Plaeido S, Bianeo AR, et al. A prognostic model that makes quantitative estimates of probability of relapse for breast cancer patients. Clin Cancer Res, 1999, 5:4133-4139. 被引量:1
  • 3Linasmita V, Pattaraarchachai J, Daengdeelert P. Prognostic factors for survival of epithelial ovarian cancer, lnt J Gynecol Obstet, 2004,85:66-69. 被引量:1
  • 4Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gyneeol Oneol,1998, 69:103-108. 被引量:1
  • 5Brinkhuis M, Meijer GA, Baak JP. An evaluation of prognostic factors in advanced ovarian cancer. Eur J Obstet Gynecol Reprod Biol, 1995, 63 : 115-124. 被引量:1
  • 6Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol, 2002, 20: 1248-1259. 被引量:1
  • 7Bristow RE, Montz FJ, Lagasse LD, et al. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol, 1999, 72:278-287. 被引量:1
  • 8连丽娟.林巧稚妇科肿瘤学(第3版)[M].北京:人民卫生出版社,2001.326. 被引量:5
  • 9查曼丽,施毅,夏锡荣,童茂荣.紫杉醇加顺铂治疗非小细胞肺癌临床观察[J].医师进修杂志,1998,21(1):28-29. 被引量:4
  • 10曾涛,杨振宇,章蕴毅.进口与国产紫杉醇治疗卵巢恶性肿瘤的疗效和药物经济学评价[J].中国临床药学杂志,2011,20(5):266-270. 被引量:4

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部